AustriaAustria

GM potato banned anew

12.05.2010

Vienna – Invoking the EU’s safeguard clause, the Austrian parliament has unanimously instructed its Ministry of Health to establish a specific legal measure to prohibit the cultivation of the biotech potato Amflora in the country. Health Minister Alois Stöger signed a decree at the end of April prohibiting the cultivation of Amflora, threatening fines for transgressors. Stöger has the support of the majority of the Austrian parliament, which criticised Amflora because it carries a gene for resistance to certain antibiotics. Releasing it into the environment could raise bacterial resistance to life-saving medicines, they said, including drugs used for the treatment of tuberculosis. Austria also blamed the EU for putting the interests of potato producers before human health, and noted that Amflora cultivation is not necessary, as some conventional varieties have the same characteristics. In March, the European Commission finally greenlighted Amflora more than a decade after developer BASF SE filed the first application for approval. The decision ended what has been a long stalemate over a backlog of GM crops also awaiting authorisation. In Germany, planting Amflora has provoked protests by environment­alists, who blocked the depository warehouse where the potatoes were stored.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/gm-potato-banned-anew.html

Product of the week

Products

Events

All Events

Current issue

All issues